AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Synergy pharmaceuticals3/25/2023 ![]() Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Clinically meaningful reductions in time to resolution of clinically significant pain and in incidence of post-herpetic neuralgia were noted. “We believe that with our expanding clinical experience in utilizing patient-reported outcome tools from our GI program, a feature that will be necessary for supporting pain-related indications for FV-100, we are in a unique position to further develop FV-100 for patients not adequately treated with present-day therapy.”įV-100 earlier completed a Phase IIa clinical trial in shingles patients, in which the drug was given to a total of 230 patients composed of two cohorts of 115 patients dosed at 200 mg and 400 mg, respectively, and found to be well tolerated at both doses. ![]() “FV-100 is a drug candidate we believe has great potential to treat patients suffering from shingles,” said Dr. recently announced it has signed an Asset Purchase Agreement with Bristol-Myers Squibb Company and has acquired the assets related to FV-100, an orally available nucleoside analogue, currently being developed for the treatment of shingles, a severe, painful skin rash caused by reactivation of the varicella zoster virus – the virus that causes chickenpox.
0 Comments
Read More
Leave a Reply. |